An Expanded Access Program of CNT-01 in Patients with Idiopathic Triglyceride Deposit Cardiomyovasculopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051220160

Enrollment

Registered

2023-01-30

Start date

2023-02-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic triglyceride deposit cardiomyovasculopathy

Interventions

CNT-01 is administered orally three times daily (in the morning, at noon, and in the evening). The starting dose of CNT-01 is 500 mg (1,500 mg/day) for the first 2 weeks, then the dose is increased to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who completed the 52 weeks of administration in the CNT-01-811 study. Patients who voluntarily signed and dated the informed consent form.

Exclusion criteria

Exclusion criteria: Patients with diabetic ketoacidosis. Patients allergic to the ingredients of the investigational product.

Design outcomes

Primary

Measure	Time frame
Adverse event, Adverse drug reaction	—

Contacts

Public ContactClinical Development Dept.

TOA EIYO LTD.

ct_info@toaeiyo.co.jp+81-3-6757-1040

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026